Literature DB >> 27448444

Accumulating nanoparticles by EPR: A route of no return.

Romeo Ngoune1, Annette Peters2, Dominik von Elverfeldt3, Karl Winkler4, Gerhard Pütz5.   

Abstract

Nanoparticle-based drug delivery to ease anticancer therapy relies primarily on the enhanced permeability and retention effect (EPR). The leaky vascular structure in tumors allows extravasation of nanoparticles, often termed passive targeting. Long term retention of nanoparticles is attributed to the lack of lymphatic drainage, and unidirectional extravasation has been implied. Fluorescent liposomes with a plasma half-life of 29h were injected into tumor-bearing rats, and biodistribution in tumor, skin, paws and ears was monitored via in vivo fluorescence measurements. To calculate tissue accumulation, an algorithm was developed to subtract the blood signal from the total fluorescence recorded. Accumulation in tumor tissue was much higher than that in other tissues monitored, initially exhibiting very rapid accumulation followed by a long plateau phase with little change. Discontinuous plasmapheresis was established that was as effective as highly sophisticated clinical plasmapheresis. We observed no difference in the tumor tissue's accumulation when plasmapheresis was performed 22h after liposome injection. In contrast, plasmapheresis led to a significant inhibition of further accumulation in other tissues. When the liposomes' blood concentration was rapidly lowered, we detected no drop in tumor fluorescence. Thus extravasation via EPR is most likely a route of no return. These data support the emerging view of a more dynamic model of EPR, where gaps or entire vessels may open and close over time, or accumulated liposomes become entangled within the pores, hampering further accumulation.
Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DiI (PubChem CID 5706736); DiR (PubChem CID 25195411); EPR; In vivo imaging; PLD; Therapeutic plasmapheresis; Tumor

Mesh:

Substances:

Year:  2016        PMID: 27448444     DOI: 10.1016/j.jconrel.2016.07.028

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  34 in total

1.  Development of Liposomal Gemcitabine with High Drug Loading Capacity.

Authors:  Hassan Tamam; Jinho Park; Hytham H Gadalla; Andrea R Masters; Jelan A Abdel-Aleem; Sayed I Abdelrahman; Aly A Abdelrahman; L Tiffany Lyle; Yoon Yeo
Journal:  Mol Pharm       Date:  2019-06-14       Impact factor: 4.939

2.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

3.  64Cu-labeled melanin nanoparticles for PET/CT and radionuclide therapy of tumor.

Authors:  Huijun Zhou; Qing Zhang; Yan Cheng; Lili Xiang; Guohua Shen; Xiaoai Wu; Huawei Cai; Daifeng Li; Hua Zhu; Ruiping Zhang; Lin Li; Zhen Cheng
Journal:  Nanomedicine       Date:  2020-06-20       Impact factor: 5.307

4.  A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.

Authors:  Pei-Wen Li; Shi Luo; Lin-Yu Xiao; Bo-le Tian; Li Wang; Zhi-Rong Zhang; Ying-Chun Zeng
Journal:  Acta Pharmacol Sin       Date:  2019-04-23       Impact factor: 6.150

5.  Disulfiram enhances chemotherapeutic effects of doxorubicin liposomes against human hepatocellular carcinoma via activating ROS-induced cell stress response pathways.

Authors:  Hai Lin; Fengjie Sun; Tingting Li; Yihan Zhang; Xiaochun Guo; Ming Li; Min Liang; Xinke Zhou; Zhiyuan Fang
Journal:  Cancer Chemother Pharmacol       Date:  2022-10-17       Impact factor: 3.288

6.  Site-Specific Labeling of Cyanine and Porphyrin Dye-Stabilized Nanoemulsions with Affibodies for Cellular Targeting.

Authors:  Ahmad Amirshaghaghi; Burcin Altun; Kido Nwe; Lesan Yan; Joel M Stein; Zhiliang Cheng; Andrew Tsourkas
Journal:  J Am Chem Soc       Date:  2018-10-15       Impact factor: 15.419

Review 7.  Bioengineered Ferritin Nanocarriers for Cancer Therapy.

Authors:  Xuanrong Sun; Yulu Hong; Yubei Gong; Shanshan Zheng; Dehui Xie
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

Review 8.  Exosome-like Nanovectors for Drug Delivery in Cancer.

Authors:  Noemi Arrighetti; Claudia Corbo; Michael Evangelopoulos; Anna Pastò; Valentina Zuco; Ennio Tasciotti
Journal:  Curr Med Chem       Date:  2019       Impact factor: 4.530

Review 9.  Photodynamic Therapy and the Biophysics of the Tumor Microenvironment.

Authors:  Aaron J Sorrin; Mustafa Kemal Ruhi; Nathaniel A Ferlic; Vida Karimnia; William J Polacheck; Jonathan P Celli; Huang-Chiao Huang; Imran Rizvi
Journal:  Photochem Photobiol       Date:  2020-03-05       Impact factor: 3.421

10.  A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.

Authors:  Takeshi Matsumoto; Takashi Komori; Yuta Yoshino; Tadaaki Ioroi; Tsukasa Kitahashi; Hiromu Kitahara; Kohei Ono; Tamami Higuchi; Masayo Sakabe; Hiroshi Kori; Masahiro Kano; Ritsuko Hori; Yukio Kato; Shinji Hagiwara
Journal:  Pharm Res       Date:  2021-05-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.